Cochlear Ltd. (ASX:COH) has joined a $17.1 million (EU €15 million) funding round for Nyxoah to support the development and commercialization of its hypoglossal nerve stim therapy for treating obstructive sleep apnea. Australian hearing tech developer Cochlear lead the round, investing $14.7 million (EU €13 million). The round was also joined by several existing Nyxoah shareholders, the Belgian company said. As part of the funding round, a member of Cochlear has joined Nyxoah's board of directors. "Cochlear actively monitors the market for novel technologies and implantable devices that over the long term may leverage its core business. Nyxoah's minimally invasive solution presents an attractive alternative for patients with compliance or intolerance issues in respec...
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2K4k3Kr
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.